Rhenman & Partners Asset Management Ab Acadia Pharmaceuticals Inc Transaction History

Rhenman & Partners Asset Management Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 03, 2018	SELL	$13.03 - $21.81 $2.87 Million - $4.8 Million	-220,000 Closed	0 $0
Q2 2018 Jul 20, 2018	SELL	$15.07 - $22.34 $753,500 - $1.12 Million	-50,000 Reduced 18.52%	220,000 $3.36 Million
Q1 2018 Apr 11, 2018	SELL	$22.47 - $32.33 $1.55 Million - $2.23 Million	-68,882 Reduced 20.33%	270,000 $6.07 Million
Q4 2017 Jan 19, 2018	BUY	$26.84 - $39.14 $9.1 Million - $13.3 Million	338,882	338,882 $10.2 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.